Literature DB >> 17467560

Current issues in quality improvement in cystic fibrosis.

Hebe B Quinton1, Gerald T O'Connor.   

Abstract

The modern history of cystic fibrosis (CF) is one of continuous improvement. Guidelines and evidence-based medicine provide a general roadmap for directing improvement efforts. Data and measurement are central to quality improvement (QI), a way of keeping score and staying on track. This article describes the history and context of QI in CF, the use of guidelines and data with some examples from the work of one regional consortium, some approaches to developing QI skills with a view to implementing and managing desired changes in CF clinic settings, and the potential benefits and impact of public reporting and data transparency.

Entities:  

Mesh:

Year:  2007        PMID: 17467560     DOI: 10.1016/j.ccm.2007.02.013

Source DB:  PubMed          Journal:  Clin Chest Med        ISSN: 0272-5231            Impact factor:   2.878


  8 in total

1.  Inhaled tobramycin effectively reduces FEV1 decline in cystic fibrosis. An instrumental variables analysis.

Authors:  Rhonda D VanDyke; Gary L McPhail; Bin Huang; Matthew C Fenchel; Raouf S Amin; Adam C Carle; Barb A Chini; Michael Seid
Journal:  Ann Am Thorac Soc       Date:  2013-06

2.  Implementation of cystic fibrosis clinical pathways improved physician adherence to care guidelines.

Authors:  Sachinkumar B Singh; Annie U Shelton; Barbara Greenberg; Timothy D Starner
Journal:  Pediatr Pulmonol       Date:  2016-10-31

3.  Genes that determine immunology and inflammation modify the basic defect of impaired ion conductance in cystic fibrosis epithelia.

Authors:  Frauke Stanke; Tim Becker; Vinod Kumar; Silke Hedtfeld; Christian Becker; Harry Cuppens; Stephanie Tamm; Jennifer Yarden; Ulrike Laabs; Benny Siebert; Luis Fernandez; Milan Macek; Dragica Radojkovic; Manfred Ballmann; Joachim Greipel; Jean-Jacques Cassiman; Thomas F Wienker; Burkhard Tümmler
Journal:  J Med Genet       Date:  2010-09-12       Impact factor: 6.318

Review 4.  Maintenance of nutritional status in patients with cystic fibrosis: new and emerging therapies.

Authors:  Daina Kalnins; Michael Wilschanski
Journal:  Drug Des Devel Ther       Date:  2012-06-20       Impact factor: 4.162

5.  Comparing cystic fibrosis outcomes across the pond.

Authors:  David C Taylor-Robinson; Michael S Schechter; Rosalind L Smyth
Journal:  Thorax       Date:  2014-12-23       Impact factor: 9.139

6.  Prospectively predicting Pseudomonas aeruginosa infection/s using routine data from the UK cystic fibrosis register.

Authors:  Nikki Totton; Mike Bradburn; Zhe Hui Hoo; Jen Lewis; Daniel Hind; Carla Girling; Elizabeth Shepherd; Julia Nightingale; Thomas Daniels; Jane Dewar; Sophie Dawson; Mary Carroll; Mark Allenby; Frank Edenborough; Rachael Curley; Charlotte Carolan; Martin Wildman
Journal:  Health Sci Rep       Date:  2021-10-01

7.  Accurate reporting of adherence to inhaled therapies in adults with cystic fibrosis: methods to calculate "normative adherence".

Authors:  Zhe Hui Hoo; Rachael Curley; Michael J Campbell; Stephen J Walters; Daniel Hind; Martin J Wildman
Journal:  Patient Prefer Adherence       Date:  2016-05-23       Impact factor: 2.711

8.  Rescue therapy within the UK Cystic Fibrosis Registry: An exploration of predictors of intravenous antibiotic use amongst adults with CF.

Authors:  Zhe Hui Hoo; Martin J Wildman; Rachael Curley; Stephen J Walters; Michael J Campbell
Journal:  Respirology       Date:  2017-09-14       Impact factor: 6.424

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.